Rectal Cancer Stage III
Conditions
Keywords
rectal cancer, neoadjuvant, serum adipokines, leptin, adiponectin
Brief summary
It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.
Interventions
DIAGNOSTIC_TESTserum adipokines
Level of serum adipokines will be measured with flow cytometry
Sponsors
Istanbul Training and Research Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* All patients with locally advanced rectal cancer
Exclusion criteria
* below 18 years old * patients who did not received neoadjuvant therapyAll
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer | 1 year | The Adiponectin, Adipsin, Leptin, Resistin levels will be measured with flow cytometric analysis. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactCihad Tatar, MD
Outcome results
None listed